The moderating effect of psychedelics on the prospective relationship between prescription opioid use and suicide risk among marginalized women Elena Argento, Melissa Braschel, Zach Walsh, M. Eugenia Socias and Kate Shannon Journal of Psychopharmacology, 2018, 1–7 DOI : 10.1177/0269881118798610 Abstract Background/aims : Given high rates of depression and suicide among marginalized women, and increasing calls to integrate trauma-informed biomedical and community-led structural interventions, this study longitudinally examines the potential moderating effect of psychedelic use on the relationship between other illicit drug use and suicide risk. Methods : Data (2010–2017) were drawn from a community-based, prospective open cohort of marginalized women in Vancouver, Canada. Extended Cox regression [...]
Lire la suiteThe Potential of Cannabidiol as a Treatment for Psychosis and Addiction : Who Benefits Most ? A Systematic Review Albert Batalla, Hella Janssen, Shiral S. Gangadin and Matthijs G. Bossong Journal of Clinical Medicine, 2019, 8, 1058 doi : 10.3390/jcm8071058 Abstract : The endogenous cannabinoid (eCB) system plays an important role in the pathophysiology of both psychotic disorders and substance use disorders (SUDs). The non-psychoactive cannabinoid compound, cannabidiol (CBD) is a highly promising tool in the treatment of both disorders. Here we review human clinical studies that investigated the ecacy of CBD treatment for schizophrenia, substance use disorders, and their comorbidity. In particular, we examined [...]
Lire la suiteNabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence : A pilot randomized clinical trial Jose M. Trigo, Alexandra Soliman, Lena C. Quilty, Benedikt Fischer, JuÈrgen Rehm, Peter Selby, Allan J. Barnes11¤a, Marilyn A. Huestis, Tony P. George, David L. Streiner, Gregory Staios, Bernard Le Foll PLoS ONE, 2018, 13, (1), e0190768. https://doi.org/10.1371/journal.pone.0190768 Abstract Background The current lack of pharmacological treatments for cannabis use disorder (CUD) warrants novel approaches and further investigation of promising pharmacotherapy. We previously showed that nabiximols (27 mg/ml Δ9-tetrahydrocannabinol (THC)/ 25 mg/ml cannabidiol (CBD), Sativex®) can decrease cannabis withdrawal symptoms. Here, we assessed in a pilot study the [...]
Lire la suiteFlashback : Psychiatric Experimentation With LSD in Historical Perspective Erika Dyck Canadian Journal of Psychiatry, 2005, Vol 50, No 7, 381-388. Doi : 10.1177/070674370505000703 In the popular mind, d-lysergic acid diethylamide (LSD) research in psychiatry has long been associated with the CIA-funded experiments conducted by Ewen Cameron at the Allen Memorial Institute in Montreal, Quebec. Despite this reputation, a host of medical researchers in the post–World War II era explored LSD for its potential therapeutic value. Some of the most widespread trials in the Western world occurred in Saskatchewan, under the direction of psychiatrists Humphry Osmond (in Weyburn) and Abram Hoffer (in Saskatoon). These [...]
Lire la suitePsychological variables implied in the therapeutic effect of ayahuasca : a contextual approach. Alba Franquesa, Alberto Sainz-Cort, Sam Gandy, Joaquim Soler, Miguel Ángel Alcázar-Córcoles, José Carlos Bouso Psychiatry Research, 2017 PII: S0165-1781(17)31377-X DOI: 10.1016/j.psychres.2018.04.012 Abstract Ayahuasca is a psychedelic decoction originating from Amazonia. The ayahuasca-induced introspective experience has been shown to have potential benefits in the treatment of several pathologies, to protect mental health and to improve neuropsychological functions and creativity, and boost mindfulness. The underlying psychological processes related to the use of ayahuasca in a psychotherapeutic context are not yet well described in the scientific literature, but there is some evidence to suggest that psychological [...]
Lire la suiteLong-term effects of ayahuasca in patients with recurrent depression : a 5-year qualitative follow-up Rafael G. dos Santos, Rafael Faria Sanches, Flávia de Lima Osório, Jaime E.C. Hallak Archive of Clinical Psychiatry, 2018, 45, 1, 22-4 DOI: 10.1590/0101-60830000000149 Abstract Background : Ayahuasca is a botanical hallucinogenic preparation traditionally used by indigenous populations of Northwestern Amazonian countries for ritual and therapeutic purposes. It is rich in β-carboline alkaloids and N,N-dimethyltryptamine (DMT). Preclinical, observational, and experimental studies suggest that ayahuasca and its alkaloids have anxiolytic and antidepressive effects. We recently reported in an open-label trial that ayahuasca administration was associated with significant decreases in depression symptoms for [...]
Lire la suiteAssociation Between Marijuana Use and Adverse Obstetrical and Neonatal Outcomes CR Warshak; J Regan; B Moore; K Magner; S Kritzer; J Van Hook Journal of Perinatology, 2015, 35, 12, 991-995. PMID : 26401751 DOI : 10.1038/jp.2015.120 Abstract and Introduction Abstract Objective: To evaluate associations between marijuana exposure and adverse outcomes excluding women with polysubstance abuse and stratifying for concurrent maternal tobacco use. Study Design: We performed a retrospective cohort study evaluating various obstetrical and neonatal outcomes including: preterm delivery, pre-eclampsia, gestational diabetes, cesarean delivery, fetal growth restriction, a composite which included stillbirth or neonatal intensive care unit admission, and perinatal mortality. We stratified study groups [...]
Lire la suiteCessation and reduction in alcohol consumption and misuse after psychedelic use Albert Garcia-Romeu, Alan K Davis, Fire Erowid, Earth Erowid, Roland R Griffiths and Matthew W Johnson Journal of Psychopharmacology, 2019, 1–14 DOI: 10.1177/0269881119845793 journals.sagepub.com/home/jop Abstract Background : Meta-analysis of randomized studies using lysergic acid diethylamide (LSD) for alcohol use disorder (AUD) showed large, significant effects for LSD efficacy compared to control conditions. Clinical studies suggest potential anti-addiction effects of LSD and mechanistically-related classic psychedelics for alcohol and other substance use disorders. Aims : To supplement clinical studies, reports of psychedelic use in naturalistic settings can provide further data regarding potential effects of psychedelics on alcohol use. Methods [...]
Lire la suiteA Contemporary History of Ibogaine in the United States and Europe THE ALKALOIDS, 2001, Vol.56, Chapitre 14 Copyright © 2001 by Academic Press 0099-9598/01 Kenneth R. Alper, Dana Beal & Charles D. Kaplan I. Introduction In 1995, Dr. Curtis Wright, then the U.S. Food and Drug Administration (FDA) ibogaine project officer, wrote “What’s clear is that a significant portion of the public we serve believes the drug merits investigation” (1). Wright’s statement intimates a relationship of public opinion to regulatory scientific policy. The statement was made at a time when the FDA, partly in response to highly motivated and organized public advocacy, was modifying its drug [...]
Lire la suiteDoes cannabidiol protect against adverse psychological effects of THC ? Raymond J. M. Niesink and Margriet W. van Laar Frontiers in Psychiatry, 2013, 4, 130 doi : 10.3389/fpsyt.2013.00130. Abstract The recreational use of cannabis can have persistent adverse effects on mental health. Delta 9-tetrahydro-cannabinol (THC) is the main psychoactive constituent of cannabis, and most, if not all, of the effects associated with the use of cannabis are caused by THC. Recent studies have suggested a possible protective effect of another cannabinoid, cannabidiol (CBD). A literature search was performed in the bibliographic databases PubMed, PsycINFO, andWeb of Science using the keyword “cannabidiol.” After removing duplicate entries, [...]
Lire la suite